[{"id":"05f32670-b974-4a37-a0db-653f78c333cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04934514","created_at":"2021-06-22T15:52:41.569Z","updated_at":"2024-07-02T16:35:18.741Z","phase":"Phase 1/2","brief_title":"Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04934514","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • IAH0968"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 07/06/2021","start_date":" 07/06/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-02-20"},{"id":"96d5c501-0ce7-4ad5-8873-391efaf81e53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991518","created_at":"2023-08-14T14:10:40.096Z","updated_at":"2024-07-02T16:35:18.706Z","phase":"Phase 1/2","brief_title":"IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors","source_id_and_acronym":"NCT05991518","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • IAH0968"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-20"},{"id":"9f45cf54-5cc1-4eb7-81d5-5bf377918b4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673512","created_at":"2023-01-06T15:58:39.959Z","updated_at":"2024-07-02T16:35:18.530Z","phase":"Phase 2/3","brief_title":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05673512","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • NRAS • MSI","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IAH0968"],"overall_status":"Recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-20"}]